Yoshiyama M, Roppolo J R, de Groat W C
Department of Pharmacology, School of Medicine, University of Pittsburgh, Pennsylvania 15261, USA.
J Pharmacol Exp Ther. 1997 Feb;280(2):894-904.
The effects of glutamate receptor antagonists on urinary bladder and external urethral sphincter- (EUS) electromyogram (EMG) activity were evaluated in unanesthetized decerebrate rats. In normal rats, LY215490, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist, in small i.v. doses (1-3 mg/kg) decreased bladder contraction amplitude (BC-Amp) by 29% and EUS-EMG by 41%; whereas a large dose (10 mg/kg) completely abolished bladder and EUS-EMG activity. LY215490 injected intrathecally in small doses (0.01-0.1 microg) decreased BC-Amp by 20% and EUS-EMG by 62%; whereas large doses (1-10 microg) completely abolished bladder and EUS-EMG activity. LY215490 (0.1 microg i.t.) increased bladder capacity by 28% and decreased voiding efficiency by 44%. Combined i.t. administration of small doses of LY215490 (0.1 microg) and MK-801 (1 microg), an N-methyl-D-aspartate (NMDA) receptor antagonist, which individually had little effect on BC-Amp, markedly suppressed bladder activity. In chronic spinal rats, LY215490 (10 mg/kg i.v.) abolished EUS-EMG activity and decreased BC-Amp by 41%. Intrathecal injections of LY215490 were also less effective in chronic spinal rats; a 10-microg dose producing only a partial block (53%) of BC-Amp, but complete block of EUS-EMG. In chronic spinal rats, MK-801 (1 mg/kg i.v.) abolished EUS-EMG activity and decreased BC-Amp by 36%. Pretreatment with MK-801 (1 mg/kg i.v.) did not enhance the effect of LY215490 on bladder activity in chronic spinal rats. These data suggest that AMPA glutamate receptors have a major role in the excitatory pathways controlling bladder and EUS activity in spinal cord intact rats. However, in chronic spinal rats, AMPA and NMDA receptors are essential for EUS reflexes, but are responsible for only a part of reflex bladder activity.
在未麻醉的去大脑大鼠中评估了谷氨酸受体拮抗剂对膀胱和尿道外括约肌(EUS)肌电图(EMG)活动的影响。在正常大鼠中,α-氨基-3-羟基-5-甲基异恶唑-4-丙酸(AMPA)受体拮抗剂LY215490静脉小剂量注射(1-3mg/kg)可使膀胱收缩幅度(BC-Amp)降低29%,EUS-EMG降低41%;而大剂量(10mg/kg)则完全消除膀胱和EUS-EMG活动。鞘内注射小剂量(0.01-0.1μg)的LY215490可使BC-Amp降低20%,EUS-EMG降低62%;而大剂量(1-10μg)则完全消除膀胱和EUS-EMG活动。LY215490(0.1μg鞘内注射)可使膀胱容量增加28%,排尿效率降低44%。鞘内联合小剂量注射LY215490(0.1μg)和N-甲基-D-天冬氨酸(NMDA)受体拮抗剂MK-801(1μg),单独使用时对BC-Amp影响不大,但能显著抑制膀胱活动。在慢性脊髓损伤大鼠中,LY215490(10mg/kg静脉注射)可消除EUS-EMG活动,使BC-Amp降低41%。鞘内注射LY215490在慢性脊髓损伤大鼠中的效果也较差;10μg剂量仅能部分阻断BC-Amp(53%),但能完全阻断EUS-EMG。在慢性脊髓损伤大鼠中,MK-801(1mg/kg静脉注射)可消除EUS-EMG活动,使BC-Amp降低36%。预先用MK-801(1mg/kg静脉注射)处理并不能增强LY215490对慢性脊髓损伤大鼠膀胱活动的影响。这些数据表明,AMPA谷氨酸受体在脊髓完整大鼠控制膀胱和EUS活动的兴奋性通路中起主要作用。然而,在慢性脊髓损伤大鼠中,AMPA和NMDA受体对EUS反射至关重要,但仅对部分膀胱反射活动起作用。